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the context of allogeneic transplantation.
How can the information in the Cassaday et al. study be
used in clinical practice? The results of the current study
conﬁrm that the type of conditioning used in non-
myeloablative transplantation strategies matters and that 1
size does not ﬁt all. The results of this study and the study at
our center suggest that 90YIT should be more frequently
administered to patients with active or refractory indolent
lymphoma before transplantation. However, patients should
be treated in clinical trials. The CLL results are intriguing and
need to be conﬁrmed in other studies. Contrary to previous
ﬁndings in mouse models [6], it appears that prior exposure
to rituximab does not affect the efﬁcacy or safety of trans-
plantation with 90YIT.
Finally, this study does not address the lingering question
in allogeneic transplantation: the incidence of graft-versus-
host disease (GVHD). Over 70% of patients in this study
developed acute II to IV GVHD. This incidence appears to be
higher (23%) than observed in our transplantation studywith
90YIT [2], suggesting that the difference is related to the
GVHD prophylaxis used rather than to the innate condi-
tioning regimen. In this era of novel B cell receptor path-
wayetargeted agents, such as ibrutinib and idelalisib, it is
paramount that the safety of allogeneic transplantation be
enhanced to encourage referrals from the community.DOI of original article: http://dx.doi.org/10.1016/j.bbmt.2014.10.023.
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Marrow Transplant Research (CIBMTR) report a retrospective
database analysis of pretransplant depth of response and its
impact on transplant outcomes. This article addresses some
of the most complex problems facing not only transplanters
but the greater myeloma community as well. Should we
optimize pretransplant induction regimens to improve post-
transplant remission duration and survival? A growing
number of studies indicate that the depth of response pre-
transplant correlates with post-transplant progression-free
survival (PFS) and, in some studies, overall survival (OS) [2,3].
With the advent of technologies allowing the assessment of
progressively lower burdens of disease, these correlations
between depth of response and PFS and OS have become
more profound and with this the inclination to intensify
therapy to lessen the extent of minimal residual disease(MRD) more compelling. More and more clinical trials are
being designed in which patients with detectable MRD after
the completion of therapy are shifted to alternative, often
more intense regimens to eliminate the last vestiges of MRD.
However, we have never deﬁnitively answered the question
if doing more to achieve a greater depth of response, at the
expenses of increased toxicity, impairment of quality of life,
and potential loss of future treatment options, ultimately
translates into improved outcomes. Prior studies do not
address whether induction algorithms should include mul-
tiple regimens to achieve a greater response depth. Indeed,
this is not limited to induction therapy but is pertinent to all
myeloma care, including post-transplant consolidation and
maintenance.
Thus, important questions are generated: How many
cycles of induction therapy should we administer? Should
we treat to maximum response with 1 induction regimen?
Or, should we treat with sequential induction regimens
until we achieve a “good” response? Additional pretrans-
plant issues must be addressed, as they pertain to pre-
transplant depth of response. Three stem cell mobilization
strategiesdgrowth factor(s) alone, mobilizing chemo-
therapy that is not cytoreductive, and mobilizing regimensd
are both cytoreductive and good mobilizers. The latter,
obviously, also may improve the depth of response. If the
overall goal is pretransplant response depth, then stem cell
mobilization strategies should include cytoreductive mobi-
lization regimens.
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et al. reported in this issue of Biology of Blood and Marrow
Transplantation. These authors gleaned from the CIBMTR
database a group of 539 patients who had not achieved at
least a partial response to ﬁrst-line induction therapy. They
then asked whether additional chemotherapy to improve
induction responses pretransplant improves outcomes post-
transplant. Thus, 324 patients received additional pretrans-
plant “salvage” therapy, and these patients were compared
with 215 patients who went directly to transplant without
further treatment.
Bottom line, although 68% of the “salvage” cohort had
improved response (only 8% complete response), these pa-
tients with deeper responses did not demonstrate improved
PFS or OS in a multivariate analysis. The authors concluded
that despite greater depth of response to “salvage” therapy
pretransplant, patients did not have improved post-
transplant outcomes. In contrast, the “control group” of pa-
tients who achieved at least a partial remission to induction
therapy demonstrated superior PFS and OS, conﬁrming that
depth of response to one line of induction therapy correlates
with favorable long-term outcomes.
There are inherent ﬂaws and biases in retrospective
database analysis. Some of the more relevant ones include
the lack of a uniform induction/salvage regimen, number of
cycles of induction/salvage, the lack of access in the earlier
years of the study of proteasome inhibitors and/or newer
immunomodulatory agents, the mobilization regimen
(cytoreductive or not cytoreductive), and post-transplant
maintenance. Regardless of these ﬂaws, an important mes-
sage has been generated by this study that will almost
certainly immediately impact the clinical management of
multiple myeloma patients eligible for transplant: In the
absence of disease progression to ﬁrst-line induction ther-
apy, additional hammering of patients with sequential cycles
of “salvage” chemotherapy should not be pursued. This large
CIBMTR database analysis does not support “salvage” ther-
apy to improve the depth of response pretransplant. Instead,
patients should proceed to stem cell mobilization and sub-
sequent transplant.
Are there possible exceptions to this statement? A study
by the PETHEMA group demonstrated that patients with
progressive disease to induction therapy have dismal out-
comes when taken directly to transplant, with a median PFS
of only 6 months [4]. Should these patients be diverted to
other forms of therapy? Should they receive more intense
salvage therapy pretransplant? These are extraordinarily
complex questions. Is the failure to respond to induction
therapy merely an exceptionally powerful prognostic vari-
able or volume of disease issue that can be overcome with
application of alternative treatment regimens? Is it possiblethat the continued application of chronic therapy in the face
of inherently resistant disease is a recipe for the selection of
progressively even more resistant disease? Unfortunately,
we have learned in myeloma that resistance to one leads, at
some level, to resistance to all.
Another unanswered question not addressed by Vij et al.
is the role of multiple cycles of high-dose therapy in patients
who do not achieve optimal responses to ﬁrst-line induction
therapy. In the post-transplant setting, older studies (IFM 94
[5] and Bologna 96 [6]) indicated that patients not achieving
deep responses (very good partial response in the IFM 94 and
near complete response in the Bologna 96 studies) were
those who derived the maximal beneﬁt from tandem
transplant. Extrapolating from this older dataset, in an era
before the routine use of novel therapies, we should consider
tandem autologous transplants in induction ”failures” or, in
the cytogenetic high-risk individual, participation in a clin-
ical trial of an allogeneic transplant or autologous/allogeneic
tandem transplant.
In summary, this study by Vij et al. [1] is one of the few
efforts that legitimately addresses a profound philosophical
question in myeloma care. Is doing more to achieve greater
depth of response the ultimate goal of all therapy? Certainly,
to biologically “cure” patients (ie, eliminate every single
clonogenic cell) this has to be the goal. However, when
treatment shows this is unlikely to happen, should we get to
our best therapy as quickly as possible and avoid the reality
of greater toxicity and the selection of increased resistance
that is inherent in salvage therapy?
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